Miracle Mile Advisors adds Gilead Sciences (GILD) to its portfolio

Gilead Sciences (GILD) : Miracle Mile Advisors added new position in Gilead Sciences during the most recent quarter end. The investment management firm now holds 2,917 shares of Gilead Sciences which is valued at $238,581 , the company said in a statement filed on Jul 25, 2016 with the SEC.Gilead Sciences makes up approximately 0.08% of Miracle Mile Advisors’s portfolio.

Other Hedge Funds, Including , First Niagara Bank boosted its stake in GILD in the latest quarter, The investment management firm added 1,135 additional shares and now holds a total of 22,640 shares of Gilead Sciences which is valued at $1,851,726. Gilead Sciences makes up approx 0.52% of First Niagara Bank’s portfolio.Nordea Investment Management Ab reduced its stake in GILD by selling 63,962 shares or 2.64% in the most recent quarter. The Hedge Fund company now holds 2,356,349 shares of GILD which is valued at $204,201,204. Gilead Sciences makes up approx 0.58% of Nordea Investment Management Ab’s portfolio. Fox Run Management L.l.c. added GILD to its portfolio by purchasing 3,800 company shares during the most recent quarter which is valued at $329,308. Gilead Sciences makes up approx 0.15% of Fox Run Management L.l.c.’s portfolio.Carlton Hofferkamp Jenks Wealth Management boosted its stake in GILD in the latest quarter, The investment management firm added 1,000 additional shares and now holds a total of 29,070 shares of Gilead Sciences which is valued at $2,519,206. Gilead Sciences makes up approx 1.93% of Carlton Hofferkamp Jenks Wealth Management’s portfolio.First United Bank Trust reduced its stake in GILD by selling 620 shares or 5.06% in the most recent quarter. The Hedge Fund company now holds 11,622 shares of GILD which is valued at $996,587. Gilead Sciences makes up approx 0.84% of First United Bank Trust’s portfolio.

Gilead Sciences closed down -1.77 points or -2.18% at $79.47 with 1,94,65,672 shares getting traded on Friday. Post opening the session at $80.6, the shares hit an intraday low of $79.37 and an intraday high of $80.84 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

On the company’s financial health, Gilead Sciences reported $3.08 EPS for the quarter, beating the analyst consensus estimate by $ 0.07 according to the earnings call on Jul 25, 2016. Analyst had a consensus of $3.01. The company had revenue of $7776.00 million for the quarter, compared to analysts expectations of $7795.08 million. The company’s revenue was down -5.7 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $3.15 EPS.

Many Wall Street Analysts have commented on Gilead Sciences. Gilead Sciences was Downgraded by Argus to ” Hold” on Jul 29, 2016. Shares were Reiterated by RBC Capital Mkts on Jul 26, 2016 to “Outperform” and Lowered the Price Target to $ 105 from a previous price target of $120 .Gilead Sciences was Downgraded by Needham to ” Hold” on Jul 26, 2016.

Gilead Sciences Inc. (Gilead) is a research-based biopharmaceutical company that discovers develops and commercializes innovative medicines. The Company’s primary areas of focus include human immunodeficiency virus (HIV) liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection oncology and inflammation and serious cardiovascular and respiratory conditions. The Company’s HIV products include Stribild Complera/Eviplera Atripla Truvada Viread Emtriva Tybost and Vitekta. Its Liver Diseases products include Harvoni Sovaldi Viread and Hepsera. Zydelig is the Company’s oncology product. Its Cardiovascular products include Letairis Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.

Leave a Reply

Gilead Sciences - Is it time to Sell?

Top Brokerage Firms are advising their investors on Gilead Sciences. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.